A nice contribution of ⁦McGill_Sarcoma⁩ group to the literature on myxoid liposarcoma. Definitely, in my experience, whole-body MRI made a difference. Happy to see our publication come through. link.springer.com/article/10.100…

🔍 Exciting update alert! 🚀 Join us for a deep dive into the latest findings from the DEFI Study with Dr. Thierry Alcindor as he discusses "New Agents in Desmoid." 💡 Don't miss this insightful session! #DEFIStudy #DesmoidUpdate

That study was a tour de force! Very proud of our contribution to the topic.

My editorial mas mentioned by ⁦ESMO - Eur. Oncology⁩ Oncology News! Thanks again to ⁦JAMA Oncology⁩ for the invitation. esmo.org/oncology-news/…

Building the Evidence for Systemic Treatment in Desmoid Fibromatosis: Is a New Metronomic Regimen Another Layer in the Foundation? | JCO Global Oncology ascopubs.org/doi/10.1200/GO… Grateful to JCO Global Oncology for the invitation to write this editorial. Congratulations to the authors!

Between call schedule and family obligations, I am missing #ASCO24 . Making up for it at Shakespeare’s Romeo and Juliet performance at the Calderwood Theater in the Boston South End.

Congratulations to Kohei shitara et al. I agree with Lizzy Smyth that a subgroup analysis would be worth conducting. These results appear comparable to those of the trial we conducted RI-MUHC with mDCF and avelumab.

pubmed.ncbi.nlm.nih.gov/38995311/ pubmed.ncbi.nlm.nih.gov/38843860/ TGCT is tough to manage, with limited options. Vimseltinib, an experimental agent, was featured in 2 recent papers, with the phase 3 results being published (slightly) before the phase 1 data! Happy to have been part of the effort.

Disappointing results overall, but I’m surprised for ASPS, which is so clearly sensitive to ICI. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Happy to be in such illustrious company! I have always admired the sarcoma community, not only for its science and advocacy efforts, but also for its camaraderie and esprit de corps! Couldn’t help using my French 😊. Dana-Farber News

A thoughtful editorial by my colleague ⁦Dayo Fadelu⁩ et al about the need for adapted guidelines while ultimately trying to get the best for our patients. I am proud to be part of ⁦ASCO⁩ Global Guidelines Advisory Board. ascopubs.org/doi/10.1200/GO…

Online First: Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial #GIST #cancer thelancet.com/journals/lanon…

Thank you OncoDaily for the chance to review the progress we've made in understanding & treating #Liposarcoma, a rare #sarcoma of fat cells - including targeted, immune, + cellular therapies & the work we need to do to improve outcomes Shushan Hovsepyan Dana-Farber Dana-Farber News

Excellent article reviewing many principles for radiotherapy in sarcomas. ascopubs.org/doi/10.1200/JC…

According to ⁦ESMO - Eur. Oncology⁩ , I am still in Montreal; or, maybe that was an oversight from my part, by not updating my profile. Regardless, it’s a pleasure to run into my 🇨🇦 🇺🇸 and 🌎 colleagues. If anyone from 🇭🇹 is around, let me know!

Great #ESMO24 symposium on response of localized sarcomas to neoadjuvant therapy (chemo or radiation). Challenges exist in defining what is a meaningful response, but radiologists and pathologists are our best allies!

SPACE-FLOT: A retro study about the impact of adj FLOT in GEA after receipt of neoadj FLOT. No apparent benefit in complete and minimal responders. Not a definitive conclusion, given methodological limitations, but useful data for certain situations. #ESMO24

Intriguing data suggesting regorafenib ➡️ PFS benefit in non-adipocytic STS after CR/PR/SD from dox-based treatment. Trend for OS noted. Which % of placebo patients went on rego after progression?

Very pleased to give a talk entitled « Learning in the basics: Desmoid Tumors 101 » at Desmoid Tumor Research Foundation 2024 Patient meeting in Houston, TX. Proud to add advocacy to clinical care, teaching and research. Dana-Farber News . Thank you for the invitation.

Another debate during this Desmoid Tumor Awareness Month. Join us! Dana-Farber News , Desmoid Tumor Research Foundation